key: cord-0716624-mgklcrnx authors: Scorei, Ion Romulus; Biţă, Andrei; Mogoşanu, George Dan title: Boron enhances the antiviral activity of the curcumin against SARS-CoV-2 date: 2020-12-21 journal: Rom J Morphol Embryol DOI: 10.47162/rjme.61.3.39 sha: b6487840f930c2696622b18d01dfc007b13fd688 doc_id: 716624 cord_uid: mgklcrnx nan It is well known that curcumin' inhibition activity on human immunodeficiency virus (HIV)-1 and HIV-2 proteases was reduced, while when rosocyanine was used its inhibition activity on HIV-1 and HIV-2 proteases increased more than 10-fold [20] . As a result, boron compounds with curcumin began to be investigated more and more, discovering remarkable biological properties (antitumor, antiviral, antioxidant, antithrombotic). It is believed that in the future these compounds could be used as drugs in the prophylaxis of pandemic viral attacks, such as SARS-CoV-2, as well as to improve blood circulation in the body. Considering the scientific arguments presented above and also the ability of curcumin to form boron complexes, several boron-based compounds could be prepared for the prevention of COVID-19 viral disease [21] . Heterozygous beta-thalassemia (HBT) is a benign genetic deficiency of the blood caused by a hereditary reduction in beta-globin synthesis. HBT is prevalent in many regions of the world, including the Mediterranean countries, the northern coast of Africa, the Middle East, Central Asia, Southeast Asia, the Far East, and South America. The highest frequencies carrying beta-thalassemia were reported in Cyprus (14%), Sardinia (10.3%) and Southeast Asia (Cambodia, Bangladesh, Thailand, Laos, etc.) [22] . The population with HBT has developed a defense mechanism for bacteria and viruses that attack the blood through the action of two toxic factors: low blood iron levels and the presence of free hemin [porphyrin that contains iron(III) and chloride]. Probably the same mechanism is happening in case of SARS-CoV-2 infection too. The above-mentioned countries had and still have a very small population infected with SARS-CoV-2 [23, 24] . In order to help elucidating future treatment decisions for COVID-19, we are proposing that the HBT model to protect the blood against SARS-CoV-2 infection. Thus, we propose to utilize the following two classes of natural compounds suited for defending the blood against SARS-CoV-2: hemin and boron-curcumin complexes. The advantages of the HBT model in identifying prophylactic and therapeutic strategies against COVID-19 are related to the following physiological aspects: (i) HO-1 has a significant activity in the spleen of HBT patients in the degradation of hemoglobin during red blood cells recycling (0.8% of the red blood cells fund per day), which represents approximately 80% of the production of endogenous carbon monoxide (CO)-derived heme [25] . (ii) HBT patients have hemin concentration in the blood, while normal people have a total lack of free hemin [23] . (iii) In HBT patients, erythropoietin (EPO), the hormone that regulates erythrocyte production, is also dramatically increased in response to anemia and hypoxia. EPO-induced HO-1 expression is likely to provide cytoprotection against oxidative stress [26] . These effects are actually a link between EPO and HO-1. In addition to HO-1 induction, EPO can exert its antioxidant effects by inducing antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase [27, 28] . (iv) Two platelet function markers belonging to the group of membrane glycoproteins -selectin P and serum soluble cluster of differentiation 40 ligand (sCD40L) -were present at lower levels in individuals with HBT compared to controls [29] . Subjects with HBT have a lower frequency of cardiac and cerebral ischemic events than controls in some studies and this difference was supported by a meta-analysis and recently multiple sclerosis is very low in thalassemics [30] . HO-1 is a metabolic enzyme that catalyzes the degradation of heme into CO, biliverdin and free iron [25] . This enzyme has anti-inflammatory and antioxidant properties, which modulate innate and adaptive immune responses. In addition, recent studies have reported that HO-1 may exert significant antiviral activity against a wide variety of viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, influenza virus, respiratory syncytial virus, dengue virus, and Ebola virus, among others [31] . The activation of HO-1 by its substrate hemin ensured the protection against HIV infection. Treatments against viral infections that enhance HO-1 include various anesthetics (isoflurane or sevoflurane), hemin, estrogen, statins, curcumin, resveratrol, and melatonin [32] . Therefore, HO-1 expression can be strongly induced by heme analogues, such as hemin and curcumin derivatives, such as boron-curcumin complexes [33, 34] . Lymphocytopenia is a common feature of SARS-Cov-2 infection, which can be used as an early marker in patients with SARS-CoV-2 infections, and is more pronounced in patients infected with SARS-CoV-2. Current data show that hemin can ameliorate lung damage resulting from virus infection. In addition, reports indicate that hemin may alleviate lung damage caused by other factors, such as lipopolysaccharide, mechanical ventilation, complement activation, and transfusion. All these results suggest that the effect of hemin in protecting the lungs has a broad spectrum and potentially involves against several diseases in the clinical setting [35] . Do rosocyanine (boron-curcumin) and hemin [iron(III)-porphyrin chloride] act against SARS-CoV-2? The following candidate molecules could be able to ensure very good blood protection against SARS-CoV-2: (i) Rosocyanine is a promising and inexpensive alternative used in the photodynamic inactivation of viruses. Rosocyanine has been shown to be an extremely effective inhibitor of viral proteases (HIV-1 and HIV-2) and in addition a potent chelator of free iron. Taking into consideration the above-presented scientific arguments and also the capacity of curcumin to form boron adducts, several boron-based curcumin nutraceuticals could be prepared for viral disease (COVID-19) prevention [36] . (ii) Hemin, a commercial heme compound, used as an inducer of HO-1 has been shown to have antiviral activity. Hemin has been approved as a drug by the Food and Drug Administration (FDA) for use in patients with acute porphyria since the 1970s. Scientific data show that protoporphyrin, hemin and other natural porphyrins, as well as related metalloporphyrins, have activity against ribonucleic acid (RNA) viruses through an inhibition mechanism of viral enveloped proteases. In addition, it is also known that porphyrins can be a remarkable viral trap (for SARS-CoV-2 too), as they can be intercalated in the host cell membranes affecting the fusion of the virus with the human body. Considering the present demand of medication, it could be worth testing the antiviral properties and safety of hemin against COVID-19 [37] . Various compelling evidence indicate a possible role for hemin-induced HO-1 as a therapy strategy against the SARS-CoV-2-induced cytokine storm syndrome. Hemin-induced HO-1 might be a harmless, novel, and promising approach for controlling SARS-CoV-2 infection and limiting cytokine [38] . Recently, it has been hypothesized that heterozygous patients with HBT would develop resistance against SARS-CoV-2 due to the absence of the beta chain in hemoglobin (potential target of the virus). This hypothesis has been studied starting from the high percentages of the beta-thalassemia population present in four areas of Italy: Sardinia, Sicily, Puglia, and Emilia Romagna [39, 40] . To this end, there are two classes of natural compounds suitable for protecting the blood against SARS-CoV-2: exogenous porphyrins [41] and boron-curcumin compounds [3] . Our current approaches for prophylaxis and treatment for COVID-19, based on HBT model and on using iron as a "bargaining chip" for blood protection and boron-curcumin complex as well, should be taken into consideration by specialized agencies -FDA, World Health Organization (WHO), European Medicines Agency (EMA). We believe that new decisions for COVID-19 prophylaxis and treatment are being actually imperative due to the spread of SARS-CoV-2 infections at the present moment. The epidemiology, diagnosis and treatment of COVID-19 CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement SARS-CoV-2 invades host cells via a novel route: CD147-spike protein Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19 Transferrin receptor is another receptor for SARS-CoV-2 entry. bioRxiv Neuropilin-1 is a host factor for SARS-CoV-2 infection Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity Disrupting CD147-RAP2 interaction abrogates erythrocyte invasion by Plasmodium falciparum Covid-19: acquired acute porphyria hypothesis (edited) Determination of boron content using a simple and rapid miniaturized curcumin assay Solution conformations of curcumin in DMSO The essential medicinal chemistry of curcumin Potential inhibitor of COVID-19 main protease (M pro ) from several medicinal plant compounds by molecular docking study Destabilizing the structural integrity of SARS-CoV-2 receptor proteins by curcumin along with hydroxychloroquine: an in silico approach for a combination therapy Theoretical molecular docking study of the structural disruption of the viral 3CL-protease of COVID19 induced by binding of capsaicin, piperine and curcumin. Part 1: A comparative study with chloroquine and hydrochloroquine two antimalaric drugs Metal complexes of curcumin -synthetic strategies, structures and medicinal applications Compounds of curcumin and boric acid. Part III. Infra-red studies of rosocyanin and allied compounds Kinetics and mechanism of the thermal and hydrolytic decomposition reaction of rosocyanin Effects of curcumin-/boron-based compound complexation on antioxidant and antiproliferation activity Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes Theoretical evaluation of bortezomib and other boron-containing compounds as inhibitors of SARS-CoV-2 main protease Hemin: a possible cause of oxidative stress in blood circulation of β-thalassemia/hemoglobin E disease HbE/β-thalassemia and oxidative stress: the key to pathophysiological mechanisms and novel therapeutics Oxidative stress and iron overload in β-thalassemia: an overview Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story? Antioxidative effects of erythropoietin Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention Could heterozygous beta thalassemia provide protection against multiple sclerosis? Modulation of antiviral immunity by heme oxygenase-1 COVID-19 and heme oxygenase: novel insight into the disease and potential therapies Upregulation of heme oxygenase-1 expression by curcumin conferring protection from hydrogen peroxideinduced apoptosis in H9c2 cardiomyoblasts Effects of curcumin complexes on MDA-MB-231 breast cancer cell proliferation Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment Chloroquine and hydroxychloroquine as antimalarials and antivirals against SARS-CoV-2: the hemin factor Heme oxygenase-1 (HO-1) cytoprotective pathway: a potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome beta-thalassemia subjects immunised? Med Hypotheses, 2020 Beta-thalassemia may protect against COVID 19 Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses The authors declare that they have no conflict of interests. This article did not contain human participants or animals. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.